Comparative Pharmacology
Head-to-head clinical analysis: ARICEPT versus ENLON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARICEPT versus ENLON.
ARICEPT vs ENLON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibitor of acetylcholinesterase, increasing acetylcholine levels in the synaptic cleft of the central nervous system.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, inhibiting neuromuscular transmission.
Initial: 5 mg orally once daily for 4-6 weeks; may increase to 10 mg once daily. Maximum: 10 mg per day. Route: oral. Frequency: once daily.
Intravenous: 0.1 mg/kg followed by 1-2 mg/min infusion for reversal of neuromuscular blockade; adjust based on twitch response.
None Documented
None Documented
70 hours (terminal elimination half-life; steady-state reached in 15-21 days; once-daily dosing appropriate)
Terminal elimination half-life of 1.5-2.5 hours; prolonged in renal impairment and elderly patients
Renal (57% unchanged drug, 17% as metabolites), fecal (30%), biliary (minimal)
Primarily renal excretion of unchanged drug (85-95%), with minor fecal elimination (<5%)
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor